1 Guillaud C, Loustau V, Michel M. Hemolytic anemia in adults: main causes and diagnostic procedures. Expert Rev Hematol. 2012:229–41.
2 Grace RF, Zanella A, Neufeld EJ, Morton DH, Eber S, Yaish H, et al. Erythrocyte pyruvate kinase deficiency: 2015 status report. Am J Hematol. 2015:825–30.
3 Grace RF, Bianchi P, van Beers EJ, Eber SW, Glader B, Yaish HM, et al. Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study. Blood. 2018:2183–92.
4 van Straaten S, Bierings M, Bianchi P, Akiyoshi K, Kanno H, Serra IB, et al. Worldwide study of hematopoietic allogeneic stem cell transplantation in pyruvate kinase deficiency. Haematologica. 2018:e82–e6.
5 Grace RF, Mark Layton D, Barcellini W. How we manage patients with pyruvate kinase deficiency. Br J Haematol. 2019:721–34.
6 Kung C, Hixon J, Kosinski PA, Cianchetta G, Histen G, Chen Y, et al. AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiency. Blood. 2017:1347–56.
7 van Beers EJ, van Straaten S, Morton DH, Barcellini W, Eber SW, Glader B, et al. Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study. Haematologica. 2019:e51–e3.
8 Ballas SK, Zeidan AM, Duong VH, DeVeaux M, Heeney MM. The effect of iron chelation therapy on overall survival in sickle cell disease and beta-thalassemia: A systematic review. Am J Hematol. 2018:943–52.